stoxline Quote Chart Rank Option Currency Glossary
  
Quince Therapeutics, Inc. (QNCX)
1.05  -0.01 (-0.94%)    04-23 10:25
Open: 1.05
High: 1.0699
Volume: 12,808
  
Pre. Close: 1.06
Low: 1.05
Market Cap: 45(M)
Technical analysis
2024-04-23 10:20:16 AM
Short term     
Mid term     
Targets 6-month :  1.29 1-year :  1.46
Resists First :  1.11 Second :  1.25
Pivot price 1.02
Supports First :  0.88 Second :  0.74
MAs MA(5) :  1.04 MA(20) :  1.04
MA(100) :  1.16 MA(250) :  1.23
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  72.4 D(3) :  66.6
RSI RSI(14): 46.4
52-week High :  1.74 Low :  0.83
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ QNCX ] has closed below upper band by 31.8%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.1 - 1.11 1.11 - 1.11
Low: 1 - 1 1 - 1.01
Close: 1.05 - 1.06 1.06 - 1.07
Company Description

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Headline News

Tue, 02 Apr 2024
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 - InvestorPlace

Mon, 01 Apr 2024
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - Business Wire

Fri, 08 Mar 2024
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech - Yahoo Finance

Thu, 22 Feb 2024
Quince Therapeutics Launches Scientific Advisory Board - Business Wire

Thu, 15 Feb 2024
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors - Yahoo Finance

Thu, 15 Feb 2024
Quince Therapeutics Appoints Rajiv Patni to Board of Directors - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 43 (M)
Shares Float 27 (M)
Held by Insiders 17 (%)
Held by Institutions 28.1 (%)
Shares Short 1,860 (K)
Shares Short P.Month 1,900 (K)
Stock Financials
EPS -0.84
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.98
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -11.4 %
Return on Equity (ttm) -33.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -18 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -1.25
PEG Ratio 0
Price to Book value 0.53
Price to Sales 0
Price to Cash Flow -2.49
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android